Evidence map›Paper›PMID 42570239›Full record

ArticleCell reports2026

APOE3 and APOE4 human astrocytes differentially modulate Alzheimer's disease pathology and microglial responses in chimeric mice.

Joan Cruz-Sese, Marta Mirón-Alcala, María Alfonso-Triguero, Jon Olalde, Leire Ruiz, Nuria Galbis-Gramage, Lorea Cortes, Laura Escobar, Pranav Preman, An Snellinx and 11 more

Abstract read
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Joan Cruz-SeseAchucarro Basque Center for Neuroscience, Leioa, Spain; Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain.
Marta Mirón-AlcalaAchucarro Basque Center for Neuroscience, Leioa, Spain; Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain.
María Alfonso-TrigueroAchucarro Basque Center for Neuroscience, Leioa, Spain; Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain.
Jon OlaldeAchucarro Basque Center for Neuroscience, Leioa, Spain.
Leire RuizAchucarro Basque Center for Neuroscience, Leioa, Spain.
Nuria Galbis-GramageAchucarro Basque Center for Neuroscience, Leioa, Spain; Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain.
Lorea CortesAchucarro Basque Center for Neuroscience, Leioa, Spain.
Laura EscobarAchucarro Basque Center for Neuroscience, Leioa, Spain.
Pranav PremanVIB Center for Brain & Disease Research, Leuven, Belgium; Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.
An SnellinxVIB Center for Brain & Disease Research, Leuven, Belgium; Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium.
Takashi SaitoDepartment of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takaomi C SaidoLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Laura Saiz-AúzFundacion CIEN, Madrid, Spain.
Alberto Rábano-GutiérrezFundacion CIEN, Madrid, Spain.
Ana M AransayCenter for Cooperative Research in Biosciences (CIC BioGUNE), Science and Technology Park of Bizkaia, 48160 Derio, Spain; Centre for Networked Biomedical Research on Liver and Digestive Diseases (CIBERehd -ISCIII), Madrid, Spain.
Ibai DiezComputational Neuroimaging Lab, Biobizkaia Health Research Institute, Barakaldo, Spain; IKERBASQUE Basque Foundation for Science, Bilbao, Spain; Center for Inflammation Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Julia TcwBoston University, Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Alison GoateDepartment of Genetics and Genomics Sciences, Ronald M. Loeb Center for Alzheimer's Disease, Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bart De StrooperVIB Center for Brain & Disease Research, Leuven, Belgium; Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, Leuven, Belgium; UK Dementia Research Institute, University College London, London, UK.
Elena AlberdiAchucarro Basque Center for Neuroscience, Leioa, Spain; Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain.
Amaia M ArranzAchucarro Basque Center for Neuroscience, Leioa, Spain; Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain; IKERBASQUE Basque Foundation for Science, Bilbao, Spain. Electronic address: amaia.arranz@achucarro.org.

Funding

Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI Takahisa Kanekiyo · 2021 to 2026
$42.0M
Elucidating endolysosomal trafficking dysregulation induced by APOE4 in human astrocytesR01AG082362 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Julia TCW · 2023 to 2026
$3.3M
Microglia targeted interventions in prodromal Alzheimer's disease stageR01AG083941 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Julia TCW · 2023 to 2026
$3.2M
NIA NIH HHS R01 AG082362NIA NIH HHS R01 AG083941NIA NIH HHS U19 AG069701
6 · The paper itself

Abstract

Astrocytes and APOE are strongly implicated in Alzheimer's disease (AD), yet the impact of astrocytes carrying different APOE variants on AD hallmarks remains incompletely understood. Here, we generate a chimeric model of AD by transplanting isogenic APOE3 or APOE4 human induced pluripotent stem cell-derived astrocyte progenitors into neonatal AD mice. Donor cells differentiate into human astrocytes that integrate into the cortex and display morphologies consistent with interlaminar-like astrocytes. APOE3 and APOE4 astrocytes differ in expression of APOE, which associates differentially with Aβ plaques. Notably, APOE3 astrocytes are associated with reduced Aβ burden, Tau pathology, and neuritic dystrophy, whereas APOE4 astrocytes exacerbate these processes. They also induce distinct microglial responses: APOE4 astrocytes enhance microglial clustering around Aβ plaques and promote a disease-associated microglia-like state, whereas APOE3 astrocytes reduce clustering and support a more homeostatic profile. These findings highlight a role for human astrocytes and APOE-dependent astrocyte functions in modulating AD-related pathology.

Indexed as

ADAlzheimer's diseaseamyloid-betaAPOEapolipoprotein EAβchimeric miceCP: neuroscienceCP: stem cell researchhAstrocyteshiPSCshuman astrocyteshuman induced pluripotent stem cells

Identifiers

PMID42570239
PMCPMC13506673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.